As a type II transmembrane protein, prostate-specific membrane antigen (PSMA) possesses glutamate carboxypeptidase/folate hydrolase activity and is a promising target for prostate cancer imaging (211, 212). This evidence concerns the gene FOLH1 and prostate carcinoma.